FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Biologics

FDA Questions Safety/Efficacy of Bluebirds Eli-Cel

FDA says it is difficult to determine the overall benefit-risk profile of Bluebird bios eli-cel (elivaldogene autotemcel) gene therapy, indicated for ...

Biologics

FDA Panel Backs Novavax Covid-19 Vaccine

An FDA Advisory Committee votes unanimously (21 to 0) to recommend that the agency grant Novavax an emergency use authorization for its Covid-19 vacci...

Medical Devices

CDRH Reg Advisor Silverstein Joins Private Sector

CDRH Office of Device Evaluation regulatory advisor Joshua Silverstein leaves FDA for an undisclosed private sector job.

Human Drugs

CGMP, Other Violations at Aire-Master of America

FDA warns Nixa, MO-based Aire-Master of America about CGMP and other violations in its manufacturing of two hand sanitizers.

Medical Devices

Shuren Advocates for More Regulatory Flexibility Post Covid

CDRH director Jeff Shuren says that life after Covid-19 at the Center could greatly benefit from more regulatory flexibility, which was critical in ge...

Biologics

FDA Approves GSKs Measles Vaccine

FDA approves a GSK BLA for Priorix (measles, mumps and rubella vaccine) for use in individuals 12 months of age and older.

Biologics

Bristol Myers Withdraws sBLA for Reblozyl

Bristol Myers Squibb withdraws a supplemental BLA for Reblozyl (luspatercept-aamt) for treating anemia in adults with non-transfusion dependent beta t...

Federal Register

Guide on Device Meetings/User Fee Submissions Withdrawn

Federal Register notice: FDA withdraws its guidance entitled Effects of the Covid-19 Public Health Emergency on Formal Meetings and User Fee Applicati...

Human Drugs

Complete Response Letters Not for Judicial Review: Court

An appeals court rules that it does not have jurisdiction to hear disputes arising from FDA complete response letters because they are not final agenc...

WA State Court Backs Learned Intermediary in DTC Case

The Washington State Supreme Court rules that doctors, and not drug companies, bear responsibility to warn patients about potential adverse events whe...